Joseph Truitt currently serves as the Chief Executive Officer (CEO) and Board Director of iECURE, Inc. Mr. Truitt previously was CEO of BioSpecifics Technologies Corp., which was acquired by Endo Pharmaceuticals. Prior to BioSpecifics, Mr. Truitt served as CEO of Achillion Pharmaceuticals. He joined Achillion from Viropharma, Inc. following its acquisition of Lev Pharmaceuticals. At Lev, Mr. Truitt was Vice President of Business Development and Product Strategy, leading the build out of the commercial team and infrastructure in preparation for product launch. He also served as Vice President of Sales and Operations at Johnson & Johnson, where he directed commercial operations for the company’s OraPharma subsidiary. Mr. Truitt is Chairman of the board at Larimar Therapeutics and serves on the board of Code BioTherapeutics. Mr. Truitt served as a Captain in the United States Marine Corps. He holds a BS in Marketing from LaSalle University and an MBA from St. Joseph’s University.
